Table 2. Univariate analysis of prognostic factors in the training cohort.

	Overall survival (months)
Variables	N=255	Median	95% CI	P-value (log-rank)
Year of resection
2005–2008	121	31.0	19.5–42.4	0.610
2009–2012	134	32.6	21.9–43.3
Age (years)
⩽50	126	26.1	20.8–31.4	0.063
>50	129	40.9	26.7–55.1
Sex
Male	227	31.5	22.7–40.4	0.715
Female	28	28.2	7.8–48.6
Aetiology
Viral	231	32.6	24.3–41.0	0.695
Others	24	17.0	9.9–24.1
Portal hypertension
Yes	56	24.2	23.5–41.8	0.168
No	199	32.6	11.3–37.1
Liver cirrhosis
Yes	181	30.6	21.7–39.5	0.190
No	74	34.5	7.1–61.8
Platelet count, 109 l−1
⩽100	22	40.9	23.7–58.1	0.468
>100	233	31.0	22.9–39.1
Prothrombin time, s
⩽12	122	46.6	25.9–67.3	0.008
>12	133	24.2	14.8–33.6
Alanine transaminase, U l−1
⩽40	148	30.6	20.2–40.9	0.478
>40	107	32.6	21.8–43.5
Aspartate aminotransferase, U l−1
⩽45	163	40.9	27.0–54.9	0.004
>45	92	20.2	11.5–28.9
Total bilirubin, μmol l−1
⩽17	192	30.1	23.4–36.9	0.533
>17	63	40.6	29.5–51.6
Serum albumin, g l−1
⩽36	22	52.7	0.0–106.5	0.826
>36	233	31.5	23.9–39.1
Alkaline phosphatase, U l−1
⩽200	250	32.3	23.9–40.7	0.008
>200	5	27.8	0.0–18.2
Glutamyl transpeptidase, U l−1
⩽100	172	42.7	28.5–56.9	0.001
>100	83	19.3	12.9–25.8
MELD score
⩽4	134	30.1	22.6–37.7	0.962
>4	121	35.0	25.4–44.6
ALBI score
Grade 1	185	34.5	24.6–44.3	0.147
Grade 2/3	70	23.4	15.2–31.5
Alpha-fetoprotein, ng ml−1
⩽200	115	40.9	23.4–58.4	0.008
>200	140	28.2	21.6–34.8
Tumour extent
Unilobar	203	31.5	16.8–46.2	0.181
Bilobar	52	31.0	20.3–41.7
Tumour size (cm)a
⩽6	107	51.0	33.4–68.6	<0.001
6–9	88	28.2	21.1–35.2
⩾9	60	18.6	14.3–22.8
Tumour number
⩽3	178	49.4	34.7–64.2	<0.001
>3	77	17.6	15.1–20.2

Abbreviations: CI=confidence interval; MELD=model for end-stage liver disease; ALBI score=albumin–bilirubin score.

^aMaximum tumour size.